News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,197 Results
Type
Article (8017)
Company Profile (143)
Press Release (480037)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166741)
Career Advice (304)
Deals (25740)
Drug Delivery (7)
Drug Development (52874)
Employer Resources (14)
FDA (9761)
Job Trends (8572)
News (238195)
Policy (17898)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (499)
Accelerated approval (29)
ADA (18)
Adcomms (1)
Allergies (102)
Alliances (33157)
ALS (121)
Alzheimer's disease (1001)
Antibody-drug conjugate (ADC) (329)
Approvals (10476)
Artificial intelligence (369)
ASCO (160)
Autoimmune disease (241)
Automation (33)
Bankruptcy (263)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (42)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (24)
Bladder cancer (145)
Brain cancer (35)
Breast cancer (544)
Cancer (4029)
Cardiovascular disease (237)
Career advice (245)
Career pathing (1)
CAR-T (187)
CDC (2)
CDMO (29)
Celiac Disease (3)
Cell therapy (514)
Cervical cancer (36)
Clinical research (48461)
Collaboration (1360)
Commercialization (25)
Compensation (1614)
Complete response letters (36)
COVID-19 (771)
CRISPR (68)
C-suite (860)
Cystic fibrosis (89)
Data (6383)
Denatured (4)
Depression (108)
Dermatology (97)
Diabetes (382)
Diagnostics (4265)
Digital health (41)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (170)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (73990)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (237)
Events (88810)
Executive appointments (739)
Eye disease (3)
FDA (12680)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (997)
Gene editing (132)
Generative AI (13)
Gene therapy (352)
GLP-1 (312)
Government (952)
Grass and pollen (2)
Guidances (281)
Healthcare (9393)
Hematology (95)
HIV (56)
Huntington's disease (27)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (81)
Immunology and inflammation (113)
Immuno-oncology (71)
Indications (184)
Infectious disease (978)
Inflammatory bowel disease (141)
Inflation Reduction Act (4)
Influenza (88)
Intellectual property (271)
Interviews (41)
IPO (12398)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (88)
Layoffs (59)
Legal (5195)
Licensing (48)
Liver cancer (47)
Longevity (26)
Lung cancer (580)
Lung diease (9)
Lymphoma (269)
Machine learning (30)
Management (3)
Manufacturing (619)
Marketing (20)
MASH (122)
Medical affairs (2)
Medical device (8715)
Medtech (8904)
Mergers & acquisitions (14459)
Metabolic disorders (771)
mRNA (73)
Multiple sclerosis (117)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (242)
Neuropsychiatric disorders (40)
Neuroscience (1951)
Neurotech (2)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (242)
Opinion (10)
Ovarian cancer (181)
Pain (193)
Pancreatic cancer (231)
Parkinson's disease (217)
Partnered (12)
Patents (524)
Patient advocacy (3)
Patient recruitment (549)
Patient selection (45)
Peanut (33)
People (41533)
Peptides (15)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15640)
Phase 2 (21652)
Phase 3 (14622)
Pipeline (8475)
Policy (18)
Postmarket research (1570)
Preclinical (6597)
Press Release (34)
Prostate cancer (208)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (625)
Real estate (3025)
Recruiting (6)
Regenerative medicine (13)
Regulatory (15191)
Reports (23)
Research institute (591)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (110)
Series A (176)
Series B (126)
Service/supplier (5)
Sickle cell disease (65)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (56)
Tariffs (2)
Vaccines (352)
Venture capital (17)
Weight loss (77)
Wet AMD (3)
Women's health (100)
Date
Today (125)
Last 7 days (476)
Last 30 days (1755)
Last 365 days (19243)
2026 (15829)
2025 (19251)
2024 (22987)
2023 (26538)
2022 (34587)
2021 (37167)
2020 (33468)
2019 (23257)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24264)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20442)
2010 (20333)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (321)
Arkansas (12)
Asia (18070)
Australia (2123)
California (12944)
Canada (3373)
China (585)
Colorado (533)
Connecticut (452)
Delaware (228)
Europe (24806)
Florida (1943)
Georgia (411)
Hawaii (3)
Idaho (46)
Illinois (776)
India (60)
Indiana (335)
Iowa (19)
Japan (456)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (27)
Maryland (1279)
Massachusetts (8464)
Michigan (322)
Minnesota (601)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (134)
New Hampshire (61)
New Jersey (2849)
New Mexico (12)
New York (3033)
North Carolina (1373)
North Dakota (4)
Northern California (6550)
Ohio (305)
Oklahoma (15)
Oregon (17)
Pennsylvania (2414)
Puerto Rico (24)
Rhode Island (31)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5404)
Tennessee (128)
Texas (2138)
United States (41949)
Utah (392)
Vermont (1)
Virginia (168)
Washington D.C. (39)
Washington State (996)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
488,197 Results for "opgen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
OpGen Provides Update on Business Operations and Strategic Opportunities
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000.
April 29, 2024
·
3 min read
BioCapital
OpGen Announced 1-for-10 Reverse Stock Split - May 16, 2024
OpGen, Inc. announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock.
May 16, 2024
·
4 min read
BioCapital
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
OpGen, Inc. announced that it received a notice from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250 due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
April 23, 2024
·
3 min read
BioCapital
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
OpGen, Inc. announced today a major feature upgrade for the AREScloud platform that has been implemented with our healthcare clients to enhance genomic surveillance.
August 7, 2023
·
4 min read
Business
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
November 14, 2023
·
10 min read
Deals
OpGen Announces Acquisition of Preferred Stock by David Lazar
OpGen, Inc., announced that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million.
March 25, 2024
·
6 min read
Business
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported that its German subsidiary Curetis GmbH has signed an extended and continued research and development collaboration agreement with FIND.
August 3, 2023
·
6 min read
Business
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
OpGen, Inc. reported today that its German subsidiary Curetis GmbH has met all milestones under its extended and expanded research and development (“R&D”) collaboration agreement with FIND.
July 19, 2023
·
5 min read
Business
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
OpGen, Inc. reported that it has completed two interim milestones as part of its collaboration project with InfectoGnostics under the PREPLEX grant.
April 3, 2023
·
5 min read
Business
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
August 10, 2023
·
11 min read
1 of 48,820
Next